Table 2 Bioassays for PD-L1 expression
From: Recent development in clinical applications of PD-1 and PD-L1 antibodies for cancer immunotherapy
Antibodies | Bioassays |
|---|---|
Pembrolizumab | Dako 22C3 |
Nivolumab | Dako 28-8 |
Atezolizumab | Ventana SP142 |
Durvalumab | Ventana SP263 |
Avelumab | NA |